News : K201

View:
 

Found press releases

 

MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA

11/20/2009 8:05 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in...
Martin Ingman
 

MOBERG DERMA RECRUITS SALES & MARKETING DIRECTOR

12/9/2008 5:30 AM EST  -   MOBERG DERMA AB
The Swedish pharmaceutical company Moberg Derma today announces that it is strengthening its organization through the recruitment of Martin Ingman as Sales & Marketing Director.
Martin Ingman will be responsible for building Moberg Derma’s international network of distributors as well as the company’s sales organisation for the Nordic markets. Martin brings 15 years of experience within sales and marketing. His...
Peter Wolpert, CEO Moberg Derma
 

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...